12/5
08:02 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.
12/2
03:47 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
09:15 am
xfor
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia [Seeking Alpha]
High
Report
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia [Seeking Alpha]
11/30
03:33 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at
Wall Stre
High
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at
Wall Stre
11/29
07:17 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
High
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/25
02:00 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/22
02:11 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at
Wall Street
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at
Wall Street
11/19
01:23 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
08:03 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its price target raised by analysts at HC Wainwright from $3.50 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its price target raised by analysts at HC Wainwright from $3.50 to $5.00. They now have a "buy" rating on the stock.
11/6
08:42 pm
xfor
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/5
04:01 pm
xfor
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
Low
Report
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
11/5
03:05 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $7.50 price target on by analysts at Stifel Nicolaus.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $7.50 price target on by analysts at Stifel Nicolaus.
11/5
07:00 am
xfor
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/27
07:05 pm
xfor
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
Low
Report
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
10/24
12:26 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
12:37 am
xfor
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
High
Report
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
10/23
04:01 pm
xfor
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
High
Report
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
10/23
06:16 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at Zacks Research to a "strong-buy" rating.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by analysts at Zacks Research to a "strong-buy" rating.
10/8
12:39 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
03:48 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
05:55 pm
xfor
CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight [Yahoo! Finance]
Medium
Report
CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight [Yahoo! Finance]
9/27
09:57 am
xfor
How Analyst Sentiment on X4 Pharmaceuticals Is Shifting After Recapitalization and Leadership Changes [Yahoo! Finance]
Low
Report
How Analyst Sentiment on X4 Pharmaceuticals Is Shifting After Recapitalization and Leadership Changes [Yahoo! Finance]
9/17
07:00 am
xfor
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Medium
Report
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
9/10
04:24 pm
xfor
X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders [Seeking Alpha]
Low
Report
X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders [Seeking Alpha]